Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cost-effectiveness of adalimumab dose reduction strategies in rheumatoid arthritis
ChiCTR2300072896Phase 4Not yet recruiting
- Sponsor
- The First Affiliated Hospital of Chengdu Medical College
- Start
- Jul 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of adalimumab in rheumatoid arthritis (RA) (3 arms), sponsored by The First Affiliated Hospital of Chengdu Medical College. Primary endpoints: DAS-28 score, Total cost and 1 more. Planned start Jul 2023; status: not yet recruiting.
02
Drugs
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on ChiCTR2300072896.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300072896.